Justin Chakma
Contacto de Relaciones con Inversores en ARS PHARMACEUTICALS, INC. .
Fortuna: 2 M $ al 30/04/2024
Perfil
Justin Chakma is currently the Chief Business Officer at ARS Pharmaceuticals Operations, Inc. and ARS Pharmaceuticals, Inc. He previously held positions as the Senior Director-Business Development at Celgene Corp., Director & Corporate Development at Receptos LLC, Director & Strategy at Auspex Pharmaceuticals, Inc., Associate at Thomas, McNerney & Partners LLC, and VP, Head-Business Development & Strategy at Vedanta Biosciences, Inc. Mr. Chakma completed his undergraduate degree at the University of Toronto and holds an MBA from The Wharton School of the University of Pennsylvania.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 02/01/2024 | 236 380 ( 0.24% ) | 2 M $ | 30/04/2024 |
Cargos activos de Justin Chakma
| Empresas | Cargo | Inicio |
|---|---|---|
| ARS PHARMACEUTICALS, INC. | Contacto de Relaciones con Inversores | 01/06/2019 |
ARS Subsidiary, Inc.
 ARS Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology ARS Pharmaceuticals, Inc. develops epinephrine nasal sprays for treatment of severe allergic reactions to food, medication, and insect bites. The company was founded by Richard E. Lowenthal, Sarina Tanimoto and Robert Bell and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01/06/2019 |
Antiguos cargos conocidos de Justin Chakma.
| Empresas | Cargo | Fin |
|---|---|---|
Vedanta Biosciences, Inc.
 Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/05/2019 |
| CELGENE | Corporate Officer/Principal | 01/05/2018 |
| RECEPTOS INC | Director/Miembro de la Junta | 01/11/2015 |
Thomas, McNerney & Partners LLC
 Thomas, McNerney & Partners LLC Investment ManagersFinance Thomas, McNerney & Partners LLC (Thomas McNerney & Partner) is a venture capital subsidiary of the Coral Group Inc founded in 1998. The firm is headquartered in Minneapolis, Minnesota. | Analista de Capital Privado | 01/06/2015 |
| AUSPEX PHARMACEUTICALS INC | Director/Miembro de la Junta | 01/06/2015 |
Formación de Justin Chakma.
| University of Toronto | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| ARS PHARMACEUTICALS, INC. | Health Technology |
| Empresas privadas | 6 |
|---|---|
Thomas, McNerney & Partners LLC
Thomas, McNerney & Partners LLC Investment ManagersFinance Thomas, McNerney & Partners LLC (Thomas McNerney & Partner) is a venture capital subsidiary of the Coral Group Inc founded in 1998. The firm is headquartered in Minneapolis, Minnesota. | Finance |
ARS Subsidiary, Inc.
ARS Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology ARS Pharmaceuticals, Inc. develops epinephrine nasal sprays for treatment of severe allergic reactions to food, medication, and insect bites. The company was founded by Richard E. Lowenthal, Sarina Tanimoto and Robert Bell and is headquartered in San Diego, CA. | Health Technology |
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | Health Technology |
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Auspex Pharmaceuticals, Inc.
 Auspex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Auspex Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm focuses on the development and commercialization of novel medicines for the treatment of orphan diseases. The company was founded by Sepehr Sarshar, Thomas G. Gant and Manouchehr M. Shahbaz on February 28, 2001 and is headquartered in San Diego, CA. | Health Technology |
Receptos LLC
 Receptos LLC Pharmaceuticals: MajorHealth Technology Receptos LLC engages in the provision of developing and commercializing of therapeutic candidates for the treatment of immune and inflammatory diseases. It offers Ozanimod for relapsing multiple sclerosis, Ozanimod for inflammatory bowel disease and RPC4046 for eosinophilic esophagitis. The company was founded by Marcus F. Boehm, Robert J. Peach, William H. Rastetter, Hugh Rosen and Raymond C. Stevens on September 26, 2008 and is headquartered in San Diego, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Justin Chakma
